Vera Therapeutics, Inc. (NASDAQ:VERA - Get Free Report) SVP Joseph R. Young sold 5,714 shares of the stock in a transaction on Wednesday, April 10th. The shares were sold at an average price of $40.00, for a total value of $228,560.00. Following the completion of the sale, the senior vice president now owns 53,171 shares in the company, valued at approximately $2,126,840. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.
Vera Therapeutics Price Performance
VERA opened at $47.97 on Friday. The company has a debt-to-equity ratio of 0.49, a current ratio of 7.71 and a quick ratio of 7.71. Vera Therapeutics, Inc. has a 52-week low of $6.05 and a 52-week high of $50.78. The business's fifty day moving average is $43.39 and its 200-day moving average is $24.98.
Institutional Trading of Vera Therapeutics
Several institutional investors and hedge funds have recently modified their holdings of the business. Vanguard Group Inc. lifted its position in shares of Vera Therapeutics by 3.8% during the 4th quarter. Vanguard Group Inc. now owns 1,633,608 shares of the company's stock worth $25,125,000 after buying an additional 59,218 shares during the last quarter. Goldman Sachs Group Inc. lifted its position in shares of Vera Therapeutics by 54.6% during the 4th quarter. Goldman Sachs Group Inc. now owns 649,218 shares of the company's stock worth $9,985,000 after buying an additional 229,414 shares during the last quarter. GSA Capital Partners LLP lifted its position in shares of Vera Therapeutics by 75.5% during the 4th quarter. GSA Capital Partners LLP now owns 52,590 shares of the company's stock worth $809,000 after buying an additional 22,620 shares during the last quarter. Virtus ETF Advisers LLC bought a new stake in shares of Vera Therapeutics during the 4th quarter worth $97,000. Finally, Barclays PLC lifted its position in shares of Vera Therapeutics by 58.6% during the 4th quarter. Barclays PLC now owns 113,747 shares of the company's stock worth $1,751,000 after buying an additional 42,044 shares during the last quarter. 99.21% of the stock is currently owned by institutional investors.
Analyst Ratings Changes
Have You Seen Elon’s New A.I. Device? (Picture Inside)
From InvestorPlace | Ad
A strange new era for mankind is upon us...
And it's all thanks to Elon Musk's latest creation. Click here to see this strange device you could be wearing some day.
Elon believes A.I. is advancing so fast...
This strange new device to protect us against that A.I. threat...
VERA has been the topic of a number of research reports. Oppenheimer initiated coverage on Vera Therapeutics in a report on Thursday, January 25th. They issued an "outperform" rating and a $26.00 price objective on the stock. Cantor Fitzgerald began coverage on Vera Therapeutics in a report on Monday, January 8th. They issued an "overweight" rating on the stock. Wedbush increased their target price on Vera Therapeutics from $21.00 to $34.00 and gave the stock a "neutral" rating in a report on Thursday, March 21st. Guggenheim reissued a "buy" rating and set a $56.00 target price on shares of Vera Therapeutics in a report on Friday, April 5th. Finally, HC Wainwright reissued a "buy" rating and set a $25.00 target price on shares of Vera Therapeutics in a report on Wednesday, December 27th. One research analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Vera Therapeutics currently has an average rating of "Buy" and a consensus target price of $32.29.
Read Our Latest Analysis on VERA
Vera Therapeutics Company Profile
(
Get Free Report)
Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
